BioScrip (BIOS) Stock Price Up 6.8%

BioScrip Inc (NASDAQ:BIOS) rose 6.8% during trading on Friday . The company traded as high as $2.88 and last traded at $2.83. Approximately 1,174,173 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 1,682,085 shares. The stock had previously closed at $2.65.

BIOS has been the subject of a number of recent research reports. SunTrust Banks reiterated a “buy” rating and issued a $3.00 target price on shares of BioScrip in a research report on Friday, November 3rd. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, ValuEngine upgraded shares of BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.80.

The company has a market capitalization of $341.74, a PE ratio of -4.16 and a beta of 0.27. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same period last year, the business earned ($0.12) EPS. The firm’s revenue was down 11.5% on a year-over-year basis. equities analysts predict that BioScrip Inc will post -0.63 earnings per share for the current fiscal year.

In other news, CEO Daniel E. Greenleaf acquired 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the completion of the transaction, the chief executive officer now owns 31,000 shares in the company, valued at $62,930. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in BioScrip during the third quarter worth about $114,000. Captrust Financial Advisors acquired a new stake in BioScrip during the second quarter worth about $123,000. Voya Investment Management LLC increased its position in BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after purchasing an additional 14,867 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in BioScrip during the third quarter worth about $153,000. Finally, Goldman Sachs Group Inc. increased its position in shares of BioScrip by 65.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after acquiring an additional 25,500 shares during the last quarter. Hedge funds and other institutional investors own 84.63% of the company’s stock.

WARNING: “BioScrip (BIOS) Stock Price Up 6.8%” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

What are top analysts saying about BioScrip? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioScrip and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit